08/06/2026
NEWS: HHT is featured in the new issue of American Society of Hematology's Blood!
A study now published in print reports initial findings from CHORUS, the first national US registry created to track the impact of HHT. The report includes data from the first 600 participants enrolled across 15 HHT Centers of Excellence, and reinforces our path forward: the need for earlier diagnosis, preventive care, and the development of effective therapeutics for HHT.
Cure HHT Chief Executive Officer Marianne Sergott Clancy, shared: “The first CHORUS Registry findings are now published in print—and being featured by ASH across its library of journals and digital media, reaching more than 25,000 hematologists. That is a meaningful step forward for our community. Patients and physicians have put in the work, and the data they provided towards our registry is being used already to make the invisible burden of HHT more clear, more measurable, and harder to ignore.”
The CHORUS registry was a major achievement for Cure HHT when it was launched in 2023—the first of its kind to collect comprehensive natural history data on US patients with HHT. We are grateful for this recognition from Blood and we are hopeful this publication will help us spread awareness of HHT and its impacts.
Read the study here: https://loom.ly/-ZsCACk
Listen to the podcast here: https://loom.ly/MYCMya4
Read the accompanying commentary here: https://loom.ly/39Tv7Ps
We are incredibly grateful to our first 600 patients enrolled in CHORUS — your contributions to the future of HHT research and treatment are instrumental to the progress we make, and we could not do it without you.